Winning insights: Prize awarded to researchers investigating a new potential drug target for Chagas disease

By on

Category: Network-related events, Outreach

Our huge congratulations go to Dr Daniele Chame (above), post-doctoral research associate from the Federal University of Minas Gerais (UFMG), Brazil, and Carlos Estevez, a masters’ student at UFMG, co-recipients of the 2019 Zigman Brener award at the XXXV Annual Meeting of the Brazilian Society for Protozoology (SBPz).   Daniele and Carlos, two of our NTD Network early career researchers from Professor Santuza Teixeira’s team at UFMG, Belo Horizonte, presented their findings as a poster in the Translational Biology session during the meeting, held this year in Caxambu, Brazil, 4th-6th November.  Daniele accepted the prize alone, as Carlos was at our “Workshop in Drug Discovery” training and industry symposium, held in Mendoza, Argentina, 2nd-4th November.  
Their project, arising from a collaboration between Santuza and Dr Paul Denny (Durham University, UK), investigates the potential of an enzyme found in Trypanosoma cruzi (causing Chagas disease) as a new drug target.  Inositol phosphoceramide (IPC), a sphingolipid, is abundant in the cell membranes of T. cruzi and other protozoa, but is absent from humans and other mammals.  These researchers are investigating IPC Synthase (IPCS), catalysing the final step in the production of this sphingolipid, as a potential molecular target for drug development to treat Chagas disease. Carlos and Daniela have used Crispr-Cas9 technology to genetically manipulate laboratory strains of T. cruzi, producing mutant versions of the parasite in which the enzyme is either missing or overactive.  Their data so far suggest that parasites lacking the gene for IPCS are sickly and have a reduced ability to infect their host. 
Full characterisation of these mutants is now underway.  Carlos and Daniela, we look forward to updates of your progress!
Read their winning poster abstract here.